SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company…
- VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater…
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A.…
Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mgIndependent Safety Committee…
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of…
Independent safety review approved dose escalation and initiation of third and final dosing cohortSTAR-LLD well tolerated in all subjects dosed…
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and…
Fremont, CA, May 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing…
MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused…
Approvals Cover Both Coronary and Peripheral IVL Catheters and Generators Manufactured by ShockwaveSANTA CLARA, Calif. and SINGAPORE, May 23, 2022 (GLOBE…